Key facts
- It has raised $12.3M across 1 recorded rounds; the latest was Early Stage VC ($11.8M) in Mar 2026.
- Sage Infusion has filed 2 Form Ds with the SEC, most recently Mar 2026 ($11.8M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Sage Infusion
Funding rounds
1 roundsAbout Sage Infusion
Provider of infusion therapy services intended to treat patients with autoimmune disorders. The company offers licensed healthcare professionals administering therapies under medical supervision, transparent cost estimates with upfront pricing, and individualized financial assistance, enabling regional healthcare providers and patients to obtain coordinated outpatient intravenous care with clearer cost expectations, reduced hospital visits, and streamlined administrative processes.
- Sector
- Healthcare
- HQ
- St. Petersburg, FL, United States
- Founded
- 2019
- Employees
- 61
- Website
- sageinfusion.com/
- Ownership
- Privately Held (backing)
Sage Infusion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sage Infusion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sage Infusion in its N-PORT filings yet. We sweep new filings monthly.